317 related articles for article (PubMed ID: 26614903)
21. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.
Dietrich S; Pircher A; Endris V; Peyrade F; Wendtner CM; Follows GA; Hüllein J; Jethwa A; Ellert E; Walther T; Liu X; Dyer MJ; Elter T; Brummer T; Zeiser R; Hermann M; Herold M; Weichert W; Dearden C; Haferlach T; Seiffert M; Hallek M; von Kalle C; Ho AD; Gaehler A; Andrulis M; Steurer M; Zenz T
Blood; 2016 Jun; 127(23):2847-55. PubMed ID: 26941398
[TBL] [Abstract][Full Text] [Related]
22. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
Wilmott JS; Menzies AM; Haydu LE; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA; Long GV
Br J Cancer; 2013 Mar; 108(4):924-31. PubMed ID: 23403819
[TBL] [Abstract][Full Text] [Related]
23. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Schmid S; Siano M; Joerger M; Rodriguez R; Müller J; Früh M
Lung Cancer; 2015 Jan; 87(1):85-7. PubMed ID: 25466451
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
25. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
26. [Mechanisms of resistance to anti-BRAF treatments].
Charles J; Martel C; de Fraipont F; Leccia MT; Robert C; Busser B
Ann Dermatol Venereol; 2014 Nov; 141(11):671-81. PubMed ID: 25442471
[TBL] [Abstract][Full Text] [Related]
27. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
Bahrami A; Hesari A; Khazaei M; Hassanian SM; Ferns GA; Avan A
J Cell Physiol; 2018 Mar; 233(3):2162-2169. PubMed ID: 28407239
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib for relapsed or refractory hairy-cell leukaemia.
Baker H
Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26387749
[No Abstract] [Full Text] [Related]
29. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
30. Removing a hair of doubt about BRAF targeting.
Kreitman RJ
Blood; 2015 Feb; 125(8):1199-200. PubMed ID: 25700421
[TBL] [Abstract][Full Text] [Related]
31. [Progress of anti-tumor study based on BRAF].
Yan GR; Xu ZJ; Wang HY; Zhu WL
Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.
Chapman PB
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714462
[TBL] [Abstract][Full Text] [Related]
33. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.
Orouji E; Ziegler B; Umansky V; Gebhardt C; Utikal J
Medicine (Baltimore); 2014 Dec; 93(28):e161. PubMed ID: 25526431
[TBL] [Abstract][Full Text] [Related]
34. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Dietrich S; Hüllein J; Hundemer M; Lehners N; Jethwa A; Capper D; Acker T; Garvalov BK; Andrulis M; Blume C; Schulte C; Mandel T; Meissner J; Fröhling S; von Kalle C; Glimm H; Ho AD; Zenz T
J Clin Oncol; 2013 Jul; 31(19):e300-3. PubMed ID: 23690412
[No Abstract] [Full Text] [Related]
35. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
36. Dabrafenib in the treatment of advanced melanoma.
Medina T; Amaria MN; Jimeno A
Drugs Today (Barc); 2013 Jun; 49(6):377-85. PubMed ID: 23807941
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
38. ERK pathway inhibitors: how low should we go?
Nissan MH; Rosen N; Solit DB
Cancer Discov; 2013 Jul; 3(7):719-21. PubMed ID: 23847348
[TBL] [Abstract][Full Text] [Related]
39. Paradoxical oncogenesis: are all BRAF inhibitors equal?
Menzies AM; Kefford RF; Long GV
Pigment Cell Melanoma Res; 2013 Sep; 26(5):611-5. PubMed ID: 23795808
[TBL] [Abstract][Full Text] [Related]
40. Overcoming metastatic melanoma with BRAF inhibitors.
Hong S; Hong S; Han SB
Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]